Randomized phase II study of metronomic chemotherapy (MC) plus aromatase inhibitor (AI) versus MC alone in postmenopausal hormone receptor-positive, metastatic breast cancer (MBC), with correlative circulating endothelial cell (CEC), circulating endothelial progenitor cell (CEP), VEGF, and VEGFR levels.

Endothelial Cell ◽

Endothelial Progenitor Cell ◽

Progenitor Cell ◽

Phase Ii Study ◽

Metastatic Breast ◽

Metronomic Chemotherapy ◽

Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study

10.1158/1538-7445.sabcs17-pd3-09 ◽

2018 ◽

Author(s):

H Wildiers ◽

K Tryfonidis ◽

L dal Lago ◽

P Vuylsteke ◽

G Curigliano ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Older Patients ◽

Phase Ii Study ◽

Metastatic Breast ◽

Metronomic Chemotherapy ◽

Her2 Positive ◽

Abstract OT3-1-01: A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction chemotherapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214)

10.1158/0008-5472.sabcs13-ot3-1-01 ◽

2013 ◽

Author(s):

T Yoshinami ◽

T Nakayama ◽

M Ikeda ◽

M Iwamoto ◽

Y Komoike ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Induction Chemotherapy ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Abstract OT2-06-02: A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214)

10.1158/1538-7445.sabcs17-ot2-06-02 ◽

2018 ◽

Author(s):

M Yamaguchi ◽

T Nakayama ◽

T Yoshinami ◽

M Ikeda ◽

M Iwamoto ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Phase Ii ◽

Induction Therapy ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-1869 ◽

2011 ◽

Vol 17 (5) ◽

pp. 1147-1159 ◽

Cited By ~ 122

Author(s):

C. Kent Osborne ◽

Patrick Neven ◽

Luc Y. Dirix ◽

John R. Mackey ◽

Jean Robert ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

Oncotarget ◽

10.18632/oncotarget.20478 ◽

2017 ◽

Vol 8 (48) ◽

pp. 84224-84236 ◽

Cited By ~ 12

Author(s):

Yannan Zhao ◽

Chengcheng Gong ◽

Zhonghua Wang ◽

Jian Zhang ◽

Leiping Wang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomised Phase II Study of Palbociclib Plus Exemestane with GnRH Agonist Versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3414442 ◽

2019 ◽

Author(s):

Yeon Hee Park ◽

Tae-Yong Kim ◽

Gun Min Kim ◽

Kyung Hae Jung ◽

Seok Yun Kang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Gnrh Agonist ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Premenopausal Women ◽

Hormone Receptor Positive

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Annals of Oncology ◽

10.1093/annonc/mdx505 ◽

2018 ◽

Vol 29 (1) ◽

pp. 154-161 ◽

Cited By ~ 70

Author(s):

H.S. Han ◽

V. Diéras ◽

M. Robson ◽

M. Palácová ◽

P.K. Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058356 ◽

1993 ◽

Vol 4 (1) ◽

pp. 45-50 ◽

Cited By ~ 35

Author(s):

K. Mross ◽

C. Bohn ◽

L. Edler ◽

W. Jonat ◽

W. Queisser ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2020.01.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 238-245 ◽

Cited By ~ 2

Author(s):

Romualdo Barroso-Sousa ◽

Ian E. Krop ◽

Lorenzo Trippa ◽

Zhenying Tan-Wasielewski ◽

Tianyu Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Palliative Radiotherapy ◽

Hormone Receptor Positive

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Cited By ~ 1

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent